This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Analysts upgraded MAC, INVH, CIEN, AMH and CADL, raising ratings and several price targets.
Stocks · News reference
Candel Therapeutics shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $12 to $18.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18
B of A Securities analyst Alec Stranahan upgrades Candel Therapeutics (NASDAQ:CADL) from Neutral to Buy and raises the price target from $12 to $18.
8-K filing — Candel Therapeutics, Inc. (CADL)
Filed: 2026-09-10 AccNo: 0001193125-26-387310 Size: 231 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits